Go to Top

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer.

Our Pipeline

Our Pipeline

Dual Mechanism Selective CYP17 Lyase and AR Inhibitors

Seviteronel (VT-464), a selective CYP17 lyase and AR inhibitor and the broad collection of multiple patented chemical classes of related compounds that were invented by scientists at Viamet Pharmaceuticals are wholly owned by Innocrin. Innocrin has identified high priority leads that have high CYP17 lyase potency and selectivity. It is Innocrin’s intent to leverage its organizational expertise to advance one or more of these 2nd-generation leads into clinical development.

In addition to their potential use for the treatment of breast cancer and CRPC, inhibitors that target both CYP17 lyase and AR also have potential for the treatment of other cancers driven by the AR including ovarian, bladder, hepatocellular, and lung. Similarly, these inhibitors may also have commercial potential for the treatment of non-oncologic syndromes that are due to excess sex steroid production. These conditions include endometriosis, polycystic ovary syndrome, congenital adrenal hyperplasia, and precocious puberty, among others. Safety and convenience are important attributes of our product candidates.


.